Peptide-Based Drug Design

186 Jenssen and Aspmo
29. Walter, R., Neidle, A., and Marks, N. (1975) Significant differences in the degradation
of pro-leu-gly-NH2 by human serum and that of other species (38484). Proc.
Soc. Exp. Biol. Med. 148, 98–103.
30. Springer, C.J., Eberlein, G.A., Eysselein, V.E., Schaeffer, M., Goebell, H., and
Calam, J. (1991) Accelerated in vitro degradation of CCK-58 in blood and plasma
of patients with acute pancreatitis. Clin Chim Acta. 198, 245–253.
31. White, N., Griffiths, E.C., Jeffcoate, S.L., Milner, R.D.G., Preece, M.A. (1980) Agerelated
changes in the degradation of thyrotrophin releasing hormone by human and
rat serum. J. Endocrin. 86, 397–402.
32. Frohman, L.A., Downs, T.R., Williams, T.C., Heimer, E.P., Pan, Y.C., and Felix,
A.M. (1986) Rapid enzymatic degradation of growth hormone-releasing hormone
by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2
terminus. J. Clin. Invest. 78, 906–913.
33. Wroblewski, V.J. (1991) Mechanism of deiodination of 125I-human growth
hormone in vivo. Relevance to the study of protein disposition. Biochem.
Pharmacol. 42, 889–897.
34. Cudic, M., Lockatell, C.V., Johnson, D.E., and Otvos, L., Jr. (2003) In vitro and in
vivo activity of an antibacterial peptide analog against uropathogens. Peptides 24,
807–820.
35. Otvos, L., Jr., Snyder, C., Condie, B., Bulet, P., and Wade, J.D. (2005) Chimeric
antimicrobial peptides exhibit multiple modes of action. Int. J. Pept. Res. Ther. 11,
29–42.